Compliance Office Sees Decline In Overall Recalls, Uptick In Class I
This article was originally published in The Gray Sheet
Executive Summary
The upswing of Class I recalls in fiscal 2004 is not necessarily a cause for alarm, CDRH Office of Compliance Director Tim Ulatowski suggested at the Indiana Medical Device Manufacturers Council annual meeting in Indianapolis Oct. 26
You may also be interested in...
Zeiss Visulink Reflects Rise In Device Class I Recall Notifications
Carl Zeiss Meditec's Class I voluntary recall is part of a recent uptick in FDA announcements related to the most serious type of device recalls
IVD Recalls Should Be Viewed As “Norm” Rather Than “Exception” – Gutman
Recalls should be viewed as a mechanism to improve quality control systems in companies and laboratories, according to Office of In Vitro Diagnostic Device Evaluation & Safety Director Steve Gutman
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.